China : Medecins Sans Frontieres and health authorities combine forces in HIV/AIDS pilot project On Monday 11 August, Chinese health authorities officially agreed that the Médecins Sans Frontières supported HIV/AIDS project in Xiangfan City, in the province of Hubei, is to be a pilot project for the whole country.
Hubei province has an estimated 45, 000 HIV/AIDS sufferers, many of whom contracted HIV after selling blood to illegal blood banks several years ago, is integrated into the structures of the local health authority. In an attempt to address this problem, the Chinese Government recently started providing some ARVs in Hubei. These however mostly consist of Chinese generics, with which limited treatment alternatives are possible, some of which are seen as controversial due to their possible side-effects and lack of pre-qualification by the WHO. In Xiangfan, Médecins Sans Frontières protocols are being followed for the prophylaxis of opportunistic infections (the diseases which prey on AIDS sufferers), alternative first-line anti-retroviral treatments (ART) and second-line ART. The importance is demonstrated by the fact that it is the only such programme in the whole of China to provide both prophylaxis and ART. Médecins Sans Frontières has been working with HIV/AIDS sufferers in Xiangfan since May this year and by the end of July had carried out 104 consultations, 6 of which on children under 15 years of age. Currently 2 patients are undergoing ARV treatment and this number is set to steadily increase over the coming months. “In co-operation with the health authorities, what we are aiming to implement is a full and comprehensive package of HIV/AIDS treatment and care,” explains Fille. “This includes safe nursing techniques, voluntary counselling and testing (VCT), de-stigmatisation, patient support groups and the introduction of home-based care. It is a considerable challenge.” A further test for Médecins Sans Frontières is assuring access to the necessary drugs in the developing pharmaceutical market in China. Currently 7 drugs and 1 combination are available in the country, out of the 11 essential ARVs and 3 combinations as stipulated by the WHO. Importation is also extremely difficult in China, but as Fille concludes, “we will be exploring every possible avenue to ensure that access to these life-saving treatments is improved.”
» Read about other featured projects
|
|
||||||||||
|
|||||||||||